Benefit cohort 1: Protected from acquiring infection and, therefore, subsequently protected from any clinical disease (millions) | Benefit cohort 2: Subclinical morbidity prevented from progressing (millions) | Benefit cohort 3: Clinical disease improved (millions) | Total (millions) | |
---|---|---|---|---|
Population size | ||||
Hydrocele | 16.23 | 9.26 | 9.37 | 34.86 |
Lymphedema | 9.74 | 5.56 | 8.30 | 23.60 |
Total | 25.97 | 14.82 | 17.67 | 58.46 |
Cases of chronic disease averted | ||||
Hydrocele | 16.23 | 9.26 | 1.82 | 27.31 |
Lymphedema | 9.74 | 5.56 | 1.64 | 16.93 |
Total | 25.97 | 14.82 | 3.46 | 44.25 |